FDA Pulls Emergency Plug on Pfizer, Moderna, and Novavax COVID Shots
Published Date: 10/2/2025
Notice
Summary
The FDA is ending the emergency use permissions for Pfizer, Moderna, and Novavax COVID-19 vaccines. This means these vaccines are no longer authorized under emergency rules, signaling a shift as the pandemic changes. People and healthcare providers should note this update, but it doesn’t mean the vaccines are unsafe or unavailable through regular approvals.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
EUA Revoked for Three COVID-19 Vaccines
The FDA revoked the Emergency Use Authorizations (EUAs) for Pfizer‑BioNTech COVID‑19 Vaccine, Moderna COVID‑19 Vaccine, and Novavax COVID‑19 Vaccine, Adjuvanted, so these products are no longer authorized under emergency rules. The notice says this change does not mean the vaccines are unsafe and that they may still be available through regular (non‑emergency) approval pathways.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-19271 — 60-Day Notice of Proposed Information Collection: Standards for Success Reporting
HUD wants to update how they collect info about success stories from programs they fund. This affects organizations that report to HUD, asking them to share clearer, easier-to-understand results. They’re asking for public feedback over the next 60 days before making changes, aiming to keep things simple without adding extra costs or paperwork.
Next: 2025-19273 — Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just added new people to its blacklist, meaning their money and property in the U.S. are frozen. Americans can’t do business with these folks anymore, so watch out for blocked transactions. This move helps keep bad actors from using the U.S. financial system, effective immediately.